ReviewImmunity & ageing : I & A2022
Antibodies in action: the role of humoral immunity in the fight against atherosclerosis.
Review in Immunity & ageing : I & A, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Functional Heterogeneity of Immune Cell Subpopulations in Atherosclerosis: From Basic Mechanisms to Precision Therapy.Reviews in cardiovascular medicine · 2026Review
- Immunopathogenesis of accelerated atherosclerosis in systemic lupus erythematosus: from innate and adaptive dysregulation to clinical implications.Frontiers in immunology · 2026Review
- Anti-SARS-CoV-2 nucleoprotein IgA is associated with worse disease severity in critically ill COVID-19 pneumonia patients.Frontiers in immunology · 2026Article
- B cells and B-cell receptor repertoire features in coronary heart disease: immunopathogenic roles, clinical relevance, and therapeutic potential.Frontiers in cardiovascular medicine · 2026Review
- The cardiovascular-immune axis: crosstalk and therapy in atherosclerosis, myocarditis and vasculitis.Frontiers in immunology · 2026Review
- A guide to cell-type-specific Cre mouse models in atherosclerosis: from background strains to future directions.Frontiers in cardiovascular medicine · 2026Review
- An Immune Assay to Quantify the Neutralization of Oxidation-Specific Epitopes by Human Blood Plasma.Antioxidants (Basel, Switzerland) · 2025Article
- A bibliometric analysis of macrophage-associated immune regulation in atherosclerosis: advances in the mechanisms of pathogenesis.Frontiers in immunology · 2025Review
- A bibliometric analysis of vaccination against atherosclerosis.Human vaccines & immunotherapeutics · 2024Article
- Immunostimulation Signaling via Toll-like Receptor 2 Activation: A Molecular Mechanism ofNutrients · 2024Article
- Therapeutic Avenues to Modulate B-Cell Function in Patients With Cardiovascular Disease.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- Transcriptomic analysis reveals molecular characterization and immune landscape of PANoptosis-related genes in atherosclerosis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Article
- Impact of duck astrovirus on susceptibility to infection across duck ages.Poultry science · 2024Article
- Atherosclerosis antigens as targets for immunotherapy.Nature cardiovascular research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The sequestering of oxidation-modified low-density lipoprotein by macrophages results in the accumulation of fatty deposits within the walls of arteries. Necrosis of these cells causes a release of intercellular epitopes and the activation of the adaptive immune system, which we predict leads to robust autoantibody production. T cells produce cytokines that act in the plaque environment and further stimulate B cell antibody production. B cells in atherosclerosis meanwhile have a mixed role based on subclass. The current model is that B-1 cells produce protective IgM antibodies in response to oxidation-specific epitopes that work to control plaque formation, while follicular B-2 cells produce class-switched antibodies (IgG, IgA, and IgE) which exacerbate the disease. Over the course of this review, we discuss further the validation of these protective antibodies while evaluating the current dogma regarding class-switched antibodies in atherosclerosis. There are several contradictory findings regarding the involvement of class-switched antibodies in the disease. We hypothesize that this is due to antigen-specificity, and not simply isotype, being important, and that a closer evaluation of these antibodies' targets should be conducted. We propose that specific antibodies may have therapeutical potential in preventing and controlling plaque development within a clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.